Infliximab or rituximab for refractory Wegener's granulomatosis: Long-term follow-up. A prospective randomised multicentre study on 17 patients

Clinical and Experimental Rheumatology

Volumn 29, Issue 1 SUPPL. 64, 2011, Pages

  De Menthon, M ^a   Cohen, P ^a   Pagnoux, C ^a   Buchler M ^b   Sibilia, J ^c   Detree F ^d   Gayraud, M ^e   Khellaf, M ^f   Penalba, C ^g   Legallicier, B ^a   Mouthon, L ^a   Guillevin, Loïc ^a  

^a université Paris Cité   (France)

^b CHU BRETONNEAU   (France)

^c HÔPITAL DE HAUTEPIERRE   (France)

^d Institut Mutualiste Montsouris ^*

^e HENRI MONDOR HOSPITAL   (France)

^f Hopital Manchester Centre Hospitalier de Charleville Mezieres   (France)

^g Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

Author keywords

ANCA vasculitis; Anti CD20; Anti TNF; Infliximab; Rituximab; Wegener's granulomatosis

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID;

ADULT; AGED; ARTICLE; BRONCHITIS; BRONCHUS STENOSIS; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MALE; MULTICENTER STUDY; PLASMAPHERESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RELAPSE; REMISSION; SURVIVOR; TOOTH ABSCESS; TREATMENT FAILURE; TREATMENT RESPONSE; WEGENER GRANULOMATOSIS; ABSENCE OF SIDE EFFECTS; ASPERGILLOSIS; BRONCHOSPASM; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; FACE ERYTHEMA; MIDDLE AGED; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE; DRUG SUBSTITUTION; FEMALE; FRANCE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS; YOUNG ADULT;

EID: 79960394064     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. HOFFMAN GS, KERR GS, LEAVITT RY et al.: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
2. REINHOLD-KELLER E, BEUGE N, LATZA U et al.: An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-32.
3. PAGNOUX C, HOGAN SL, CHIN H et al.: Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts. Arthritis Rheum 2008; 58: 2908-18.
4. JAYNE D, RASMUSSEN N, ANDRASSY K et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
5. GUILLEVIN L, CORDIER JF, LHOTE F et al.: A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-98.
6. DE GROOT K, HARPER L, JAYNE DR et al.: Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 670-80.
7. ADU D, PALL A, LUQMANI RA et al.: Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Qjm 1997; 90: 401-9.
8. GÉNÉREAU T, LORTHOLARY O, LECLERQ P et al.: Treatment of systemic vasculitis with cyclophosphamide and steroids: daily oral low-dose cyclophosphamide administration after failure of a pulse intravenous high-dose regimen in four patients. Br J Rheumatol 1994; 33: 959-62.
9. BARTOLUCCI P, RAMANOELINA J, COHEN P et al.: Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford). 2002; 41: 1126-32.
10. JOSSELIN L, MAHR A, COHEN P et al.: Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann Rheum Dis 2008; 67: 1343-6.
11. KEOGH KA, WYLAM ME, STONE JH et al.: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 262-8.
12. LAMPRECHT P, VOSWINKEL J, LILIENTHAL T et al.: Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford). 2002; 41: 1303-7.
13. ORISTRELL J, BEJARANO G, JORDANA R et al.: Effectiveness of rituximab in severe Wegener's granulomatosis: report of two cases and review of the literature. Open Respir Med J 2009; 3: 94-9.
14. REGENT A, MOUTHON L: Traitements antiTNF-alpha dans les maladies auto-immunes et/ou inflammatoires systemiques. Presse Med 2009; 38: 761-73.
15. ARIES PM, HELLMICH B, VOSWINKEL J et al.: Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65: 853-8.
16. JENNETTE JC, FALK RJ, ANDRASSY K et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
17. MARIETTE X, SALMON D: French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003; 62: 791.
18. LUQMANI RA, BACON PA, MOOTS RJ et al.: Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Qjm 1994; 87: 671-8.
19. HAGEN EC, DAHA MR, HERMANS J et al.: Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53: 743-53.
20. KAPLAN E, MEIER P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
21. SEO P, SPECKS U, KEOGH KA: Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008; 35: 2017-23.
22. BRIHAYE B, AOUBA A, PAGNOUX C et al.: Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007; 25 (Suppl. 44): S23-7.
23. BRIHAYE B, AOUBA A, PAGNOUX C et al.: Rituximab reversed cardiac involvement of Wegener's granulomatosis: magnetic resonance imaging assessment. Presse Med 2008; 37: 412-5.
24. BACON PA: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005; 352: 351-61.
25. MARTINEZ DEL PERO M, CHAUDHRY A, JONES R et al.: B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol 2009; 34: 328-35.
26. MUKHTYAR C, LUQMANI R: Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis. Ann Rheum Dis 2005; 64 (Suppl. 4): iv31-6.
27. KEOGH KA, YTTERBERG SR, FERVENZA FC et al.: Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173: 180-7.
28. STASI R, STIPA E, DEL POETA G et al.: Longterm observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford). 2006; 45: 1432-6.
29. LOVRIC S, ERDBRUEGGER U, KUMPERS P et al.: Rituximab as rescue therapy in antineutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant 2009; 24: 179-85.
30. TAYLOR SR, SALAMA AD, JOSHI L et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009; 60: 1540-7.
31. FINKIELMAN JD, MERKEL PA, SCHROEDER D et al.: Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147: 611-9.
32. KHELLAF M, GODEAU B: Pneumocystose au cours des maladies systemiques. Presse Med 2009; 38: 251-9.
33. STONE J, MERKEL P, SPIERA R et al.: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-32.
34. JONES RB, COHEN TERVAERT JW, HAUSER T et al.: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-20.
35. DE LEEUW K, BIJZET J, VAN DER GRAAF AM et al.: Patients with Wegener's granulomatosis: a long-term follow-up study. Clin Exp Rheumatol 2010; 28 (Suppl. 57): S18-23.